Hepatocytes that have differentiated from human embryonic stem cells (hESCs) have great potential for the treatment of liver disease as well as for drug testing. Moreover, in vitro hepatogenesis is a powerful model system for studying the molecular mechanisms underlying liver development. DNA methylation is an important epigenetic mechanism that influences differential gene expression during embryonic development. We profiled gene expression and DNA methylation of three cell states of in vitro hepatogenesis-hESC, definitive endoderm and hepatocyte-using microarray analysis. Among 525 state-specific expressed genes, 67 showed significant negative correlation between gene expression and DNA methylation. State-specific expression and methylation of target genes were validated by quantitative reverse transcription -polymerase chain reaction and pyrosequencing, respectively. To elucidate genome-scale methylation changes beyond the promoter, we also performed high-throughput sequencing of methylated DNA captured by the MBD2 protein. We found dynamic methylation changes in intergenic regions of the human genome during differentiation. This study provides valuable methylation markers for the lineage commitment of in vitro hepatogenesis and should help elucidate the molecular mechanisms underlying stem cell differentiation and liver development.
INTRODUCTION
The generation of hepatocytes from human embryonic stem cells (hESCs) is considered an alternative source of hepatocytes for regenerative medicine and for in vitro drug testing. The liver has a remarkable regenerative capacity, but regeneration eventually fails in chronic liver disease. Liver transplantation is the only effective treatment for end-stage liver disease (1) . Current stem-cell technology shows that the use of hESCderived hepatocytes may be an alternative strategy for treating liver disease (2) . In addition, the liver is the major organ for detoxification in the human body. Thus, hESC-derived hepatocytes may also be useful for toxicological research and drug metabolism assays (3) .
Recently, several groups have reported the differentiation of hESCs to hepatocytes (4 -7). Cai et al. (4) showed that in vitro hepatogenesis occurs in three stages; hESCs differentiate first into definitive endoderm (DE) cells, then differentiate into early hepatic cells and ultimately become mature hepatocytes. For the clinical application of hESCs in liver disease, welldefined and efficient protocols of differentiation are required, but the markers used to distinguish each stage of differentiation are limited (1) .
Understanding the developmental lineage of hepatogenesis in vitro is important for the treatment of liver disease as well as for developmental biology. Epigenetic controls, including DNA methylation and histone modification, play a key role in ESC differentiation (8) . Genome-wide reprogramming of DNA methylation occurs in early germ-cell development. The parental genome undergoes active DNA demethylation after fertilization, and replication-dependent passive demethylation occurs in the pre-implantation embryo. By implantation, DNA methyltransferases become active, and DNA methylation levels increase rapidly (9) . ESCs are derived from the inner cell mass of embryos at the * To whom correspondence should be addressed at: Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, 111 Gwahangno, Yuseong-gu, Daejeon 305-806, Korea. Tel: +82 428798110; Fax: +82 428798119; Email: yongsung@kribb.re.kr blastocyst stage, which is characterized by high levels of epigenetic activity, including DNA methylation (10) .
Traditionally, DNA methylation studies have focused on proximal promoter regions. Many single-gene studies have shown that promoter methylation is associated with inactive transcription of the downstream gene. However, only a limited number of promoters show lineage-specific DNA methylation (11) . Recently, genome-wide DNA methylation studies have begun to reveal that DNA methylation in promoter-distal regions is extensively altered during developmental processes (12, 13) .
To find lineage-specific DNA methylation markers for the differentiation of hepatocytes from hESCs, we used microarrays to analyze genome-wide DNA methylation and gene expression in three differentiation states-hESC, DE and hepatocyte. We identified 16 ESC-specific, 11 DE-specific, and 40 hepatocyte-specific DNA methylation markers. We also used methylated DNA-binding domain sequencing (MBD-seq) to provide a whole-genome view of DNA methylation during in vitro hepatogenesis.
RESULTS

Profiling of gene expression and DNA methylation during differentiation of hESCs into hepatocytes
We differentiated hESCs (CHA-hES4) into hepatocytes using the three-stage method of Cai et al. (4) small modifications as described (Fig. 1A) (14) . hESCs were induced to become DE cells more efficiently by prolonged exposure to activin A under our experimental conditions. Approximately 90% of hESCs stained positive for CXCR4 (CXC motif receptor 4) antibody after 5 days of treatment with 50 ng activin A, whereas only 55% of hESCs stained positive after 3 days of treatment with 100 ng activin A (Supplementary Material, Fig. S1 ) (14) . DE cells were further differentiated into hepatocytes, and most of the resultant hepatocytes expressed serpin peptidase inhibitor A1 (SERPINA1), also known as AAT, and alpha-fetoprotein (AFP) (Fig. 1A) (14) . Gene expression of the three differentiation states (hESC, DE and hepatocyte) was profiled by Illumina BeadChip analysis. To find candidate DNA methylation markers in each state, we analyzed the methylation status of 27 578 CpG sites on the Infinium array, the widely used bisulfite-based bead array (15) . To analyze the whole-genome DNA methylation changes during in vitro hepatogenesis, we also performed MBD-seq, a sequencing-based technology that uses the methyl-CpGbinding domain of the MBD2 protein to enrich for methylated double-stranded DNA fragments (Fig. 1B) (16) .
Clustering of genes with ESC-, DE-and hepatocyte-specific expression
We performed quantitative reverse transcriptase -polymerase chain reaction (qRT-PCR) of well-known markers of each differentiation state. POU5F1 (POU class 5 homeobox 1; also known as OCT4), SOX2 (sex-determining region Y box 2) and NANOG (Nanog homeobox) are ESC markers. SOX17, FOXA2 (forkhead box A2), GATA4 (GATA-binding protein 4) and CXCR4 are DE markers. ALB (albumin), AFP, SERPINA1 and ASGR1 (asialoglycoprotein receptor 1; also known as ASGPR) are hepatocyte markers. These markers showed dramatic expression changes during differentiation ( Fig. 2A) . To find additional genes that are expressed specifically during the ESC, DE and hepatocyte stages, we clustered genes that were co-expressed with the well-known markers for each state (Fig. 2B ). Cluster 1 contains 67 genes that showed ESC-specific expression with POU5F1, SOX2 and NANOG (Supplementary Material, Table S1 ). Cluster 2 contains 83 genes that showed DE-specific expression with SOX17, FOXA2, GATA4 and CXCR4 (Supplementary Material, Table S2 ). Cluster 3 contains 375 genes that showed hepatocyte-specific expression with ALB, AFP, SERPINA1 and ASGR1 (Supplementary Material, Table S3 ).
Genes that are specifically expressed and demethylated in ESCs
Gene ontology analysis of the 67 genes in cluster 1 indicated that these genes are associated with nucleic acid metabolism, development and mRNA transcription (Supplementary Material, Fig. S2 ). Among the 67 genes, we identified 16 ESCspecific markers that showed a significant negative correlation between mRNA expression and CpG methylation in the microarray data (cutoff R , 20.3, P , 0.05; Supplementary Material, Table S4 ). Figure 3A shows mRNA expression and CpG methylation patterns of the 16 ESC-specific markers during differentiation. Looking closer, we found DPPA2 (developmental pluripotency associated 2), which has a role in maintenance of the undifferentiated state and proliferation of ESCs (17); DPEP3 (dipeptidase 3), a membrane-bound glycoprotein from the family of dipeptidases (18) ; SLC15A3 (solute carrier family 15 member 3), a proton oligopeptide cotransporter (19) ; USP44 (ubiquitin-specific peptidase 44), a deubiquitinating enzyme that has a key role in regulating the cell cycle (20) ; and LECT1 (leukocyte cellderived chemotaxin 1), which is responsible for self-renewal and pluripotent differentiation (21) . We validated the mRNA expression and DNA methylation levels of these genes in hESCs, DE and hepatocyte using qRT -PCR analysis ( Fig. 3B ) and pyrosequencing ( Fig. 3C ), respectively; the mRNA expression and DNA methylation of these genes were in accordance with the microarray data.
Genes that are specifically expressed and demethylated in DE
Gene ontology analysis of the 83 genes in cluster 2 indicated that these genes are associated with signal transduction, development, embryogenesis, cell communication and segment specification (Supplementary Material, Fig. S3 ). Among the 83 genes, we identified 11 DE-specific methylation markers that showed a significant negative correlation between mRNA expression and CpG methylation in the microarray data (cutoff R , 20.3, P , 0.05; Supplementary Material, Table S5 ). Figure 4A shows mRNA expression and CpG methylation patterns of 11 DE-specific markers during differentiation. Among these 11 markers, we found CER1 (cerberus 1), a nodal signaling inhibitor that is associated with differentiation of hESCs (22); MIXL1 (Mix1 homeobox-like 1), which plays a crucial role in morphogenesis and endoderm differentiation (23); LEFTY1 and LEFTY2 (left-right determination factors 1 and 2), which are required for left-right axis determination in early embryonic development (24) ; and VWF (von Willebrand factor), a concatenated, multifunctional protein that has a binding site for subendothelial collagen and platelets (25) . We confirmed the mRNA expression of these genes by qRT -PCR analysis (Fig. 4B ) and the DNA methylation levels by pyrosequencing (Fig. 4C) .
Genes that are specifically expressed and demethylated in hepatocyte
Gene ontology analysis for the 375 genes in cluster 3 indicated that these genes are associated with immunity and defense, transport, proteolysis, cell communication, fatty-acid metabolism and cell adhesion (Supplementary Material, Fig. S4 ). Among the 375 genes, we identified 40 hepatocytespecific methylation markers that showed a significant negative correlation between mRNA expression and CpG methylation in the microarray data (cutoff R , 20.3, P , 0.05; Supplementary Material, Table S6 ). Figure 5A shows mRNA expression and CpG methylation patterns of 40 hepatocyte-specific markers during differentiation. Looking closer, we found SERPINA3 (serpin peptidase inhibitor A3), a member of the serine protease inhibitor gene family; APOA4 (apolipoprotein A4), which plays many roles in lipid metabolism (26) ; KNG1 (kininogen 1), which plays an important role in blood coagulation (27) ; VTN (vitronectin), which promotes cell adhesion and spreading (28) ; and SULT2A1 (sulfotransferase 2A1), which catalyzes the sulfation of steroids and bile acids in the liver (29) . We validated the mRNA expression of these genes by qRT -PCR analysis (Fig. 5B ) and the DNA methylation levels by pyrosequencing (Fig. 5C ).
Expression and methylation status of identified markers in other hESCs, human induced pluripotent stem cells (iPSCs) and human liver tissue
To elucidate whether the markers described above are applicable for identifying other hESCs and human liver tissues, we analyzed expression profiles of these markers in H9 hESCs, H9 endoderm and adult liver tissue using microarray data obtained from Brunner et al. (30) . Most ESC, DE and hepatocyte markers showed expression patterns that were similar to those of well-known markers for each state (Fig. 6A) , suggesting that changes in the expression of these genes are useful for defining the state of in vitro hepatogenesis.
We next analyzed methylation status of these markers in adult liver non-tumor (NT) tissue as well as hepatocellular carcinoma (HCC) tissue using our previous Infinium array data. We also analyzed methylation status of these markers in hESCs (HUES-3 and HUES-8) and human induced pluripotent stem cell (iPSCs) (MRC-iPS-11 and MRC-iPS-19), which are derived from MRC5, a fetal lung fibroblast cell line, using Infinium array data obtained from Nishino et al. (31) . ESC markers, including POU5F1, DPPA2 and USP44, were hypermethylated in HCC and NT liver tissue, whereas they were hypomethylated in hESCs and iPSCs. Hepatocyte markers, including SERPINA3, TM4SF4, SULT2A1, DEFB1, SLPI and HSD17B2, were hypomethylated in HCC and NT liver tissue, whereas they were hypermethylated in hESCs and iPSCs ( Fig. 6B and Supplementary Material, Fig. S5 ), suggesting that state-specific hypomethylation and overexpression of these genes can be used for monitoring in vitro hepatogenesis.
Dynamic DNA methylation changes in intergenic regions during in vitro hepatogenesis
Although the Infinium arrays provide highly reproducible CpG methylation data for .14 000 genes, they show methylation status of only one or a few CpG sites per gene. To profile whole-genome DNA methylation in hESC, DE and hepatocyte, we performed MBD-seq. We divided the entire genome into 200 bp segments (a total of 15 399 219 segments) and counted the number of reads mapped within each segment. Comparison of CpG methylation levels (b-values) from Infinium array data and the sequencing reads counted on the matched segments showed good correlation (R ¼ 0.5223, P , 2.2E 2 16 in hESC; R ¼ 0.4993, P , 2.2E 2 16 in DE; R ¼ 0.5331, P , 2.2E 2 16 in hepatocyte). Hypermethylation and hypomethylation were defined as a 2-fold increase and decrease in methylation, respectively. During differentiation from hESC to DE, hypermethylation (11.3%) was more frequent than hypomethylation (3.4%), whereas during hepatocyte differentiation from DE, hypomethylation (10.4%) was more frequent than hypermethylation (4.1%; Fig. 7A ).
We next determined whether the hyper-or hypomethylated segments were related to genomic features. Promoter regions were defined as the 2 kb upstream of transcription start sites. The majority of segments with methylation changes were intergenic regions, introns and short-interspersed nuclear elements (Fig. 7B) . Although intergenic regions occupy only 7.3% of the human genome (hg18), 32-33% of the segments that were hyper-or hypomethylated were in intergenic regions (which exclude repetitive sequences), suggesting that methylation changes in intergenic regions are important for differentiation of hESCs.
DISCUSSION
We previously described epigenetic signatures, including DNA methylation and histone modification, of well-known lineage-specific markers during in vitro hepatogenesis (14) . For a given marker, although its expression level is specified in each lineage, its methylation status does not always change in accordance with its expression level. For example, the promoter region of POU5F1, an ESC marker, undergoes increased methylation during differentiation, whereas DE markers such as FOXA2 and CXCR4 are highly expressed in DE cells but are hypomethylated in all lineages. ALB, a marker of hepatocytes, is hypermethylated throughout this differentiation process (14) .
In this study, we focused on discovering methylation markers that show temporal expression and demethylation during in vitro hepatogenesis. We isolated 67 ESC-specific, 83 DE-specific, and 375 hepatocyte-specific expressed genes and then selected state-specific demethylated genes from each group. First, we identified 16 ESC-specific methylation markers (Fig. 3) . Nine of these makers were previously found to be affected by promoter methylation. POU5F1 and SOX2 are well-known markers of ESC. DPPA2 was recently shown to be demethylated and up-regulated by butyrate treatment to enhance the efficiency of iPSC derivation (32) . Six genes (SLC15A3, CRABP1, LECT1, VGF, SFRP2 and MT1G) are aberrantly methylated in cancer, but epigenetic control of these genes during embryonic development has not yet been established. The remaining seven genes (DPEP3, USP44, MT1F, MYCN, UTF1, CHST4 and PRDM14) are newly identified methylation markers.
Secondly, we found 11 DE-specific methylation markers (Fig. 4) . Four of the DE markers (GATA4, NODAL, FOXC1 and SOX17) are regulated by promoter methylation, but most of these studies were done in cancerous cells. VWF, which is an endothelial cell marker, is increased by treatment with a DNA methylation inhibitor during endothelial differentiation from bone marrow-derived multipotent adult progenitor cells (33) . LEFTY1 is hypomethylated in mouse stem cells and hypermethylated in differentiated cells (34) . In our study, LEFTY1 and LEFTY2 were hypomethylated and up-regulated in DE during hESCs differentiation. MIXL1 is expressed in DE (35) , but promoter methylation of MIXL1 has not yet been reported. CER1 and KCNK12 are also newly identified methylation markers.
Thirdly, we found 40 hepatocyte-specific methylation markers (Fig. 5) . Seven genes (AGT, AFP, TIMP3, DEFB1, DAB2, TFF1 and HSD17B2) are aberrantly methylated in various cancers. Methylation of the SERPINA3 CpG island is a potential marker for preeclampsia (36) . Tagoh et al. (37) reported that epigenetic silencing of CSF1R occurs during B-lymphopoiesis. The remaining 31 genes are newly identified methylation markers. These genes could be valuable markers for the study of in vitro hepatogenesis and liver development.
The other objective of this study was to elucidate genome-scale methylation changes during the differentiation of hESCs. DNA methylation is essential for embryonic development. The role of DNA methylation in tissue-specific gene expression is, however, controversial; single-gene studies show that promoter methylation and gene expression are negatively correlated, but promoter methylation does not always lead to decreased gene expression (38) . Among the differentiation state-specific expressed genes that we identified, only 12% (67 of 525) showed significant negative correlation between gene expression and DNA methylation in our microarray data. To identify genomic methylation changes outside of the promoter regions, we performed MBD-seq. Interestingly, methylation changes in the intergenic regions, which exclude repetitive sequences, were most extensive during differentiation (Fig. 7B) . This is in accordance with recent genome-wide DNA methylation studies. Irizarry et al. (39) found that methylation in CpG island shores, not in promoters, is most strongly related to gene expression in colon cancer. Schmidl et al. (13) showed that the majority of differentially methylated regions in T cells are located at promoter-distal sites, including enhancers. It is well known that distal regulatory regions such as enhancers and insulators are often required to establish correct gene expression patterns in mammalian cells (40) . Recent genome-wide histone modification studies have shown that the chromatin state at promoters and insulators is largely invariant across diverse cell types, but enhancers show highly cell type-specific histone modifications (41) . We suggest that DNA methylation changes in intergenic regions, especially enhancers, may have key roles in lineage-specification gene expression. Further experiments, such as histone H3 lysine 4 monomethylation and p300/CBP profiling (41) of hESC, DE and hepatocyte, may be required to investigate DNA methylation in enhancers during in vitro hepatogenesis.
In summary, we identified genes that were expressed and demethylated in a lineage-specific manner during three consecutive stages of in vitro hepatogenesis and showed dynamic DNA methylation changes throughout the human genome, especially in intergenic regions, during hESC differentiation. Our studies should help elucidate the molecular mechanisms underlying differentiation of hESCs and facilitate the development of well-defined and standardized protocols of in vitro hepatogenesis for clinical applications in liver disease.
MATERIALS AND METHODS
Differentiation of hESCs into hepatocytes
hESCs (CHA-hES4) were provided by the College of Medicine, Pochon CHA University, Seongnam, Korea. Differentiation of hESCs into hepatocytes was carried out as described (14) . Briefly, hESCs were cultured to be confluent in conditioned medium on a feeder-free system for 3 days. Then, hESCs were incubated in RPMI-1640 (HyClone, Logan, UT, USA) containing 0.5 mg/ml of albumin fraction V (Sigma-Aldrich, St Louis, MO, USA) and 50 ng/ml of activin A (Peprotech, Rocky Hill, NJ, USA) for 1 day and further cultured in the same RPMI medium supplemented with 1% insulin -transferrin-selenium (Sigma-Aldrich) for 4 days. After treatment with activin A, DE cells were harvested. For further differentiation, DE cells were cultured in hepatocyte culture medium (HCM; Lonza, Baltimore, MD, USA) containing 30 ng/ml of FGF4 (Peprotech) and 20 ng/ml of BMP2 (Peprotech) for 5 days and further incubated in HCM supplemented with 20 ng/ml of hepatocyte growth factor (Peprotech) for 5 days. Maturation of hESCs-derived hepatocytes was induced by culturing in HCM supplemented with 10 ng/ml of oncostatin M (R&D Systems, Minneapolis, MN, USA) and 0.1 mM dexamethasone (Sigma-Aldrich) for 5 days, after which hepatocytes were harvested. The medium was changed daily.
Expression assay by Human-6 Whole-Genome Expression BeadChip hESC, DE and hepatocyte expression assays were run in quadruplicate. RNA isolated from the cell line at the indicated time points was used for gene expression analysis using the Human-6 Whole-Genome Expression BeadChip (Illumina, San Diego, CA, USA), which generates expression profiles for more than 46 000 human transcripts. Biotin-labeled cRNA was produced using a linear amplification kit (Ambion, Austin, TX, USA) using 300 ng of quality-checked total RNA as input. Chip hybridizations, washing, Cy3-streptavidin staining and scanning were performed on a BeadArray Reader (Illumina) platform using reagents and following protocols supplied by the manufacturer. The detection score was used to determine expression.
Methylation assays by Infinium HumanMethylation27 BeadChip
hESCs, DE and hepatocyte methylation assays were run in triplicate. Genomic DNA (1 mg) from each sample was bisulfite converted using the EZ DNA methylation kit (Zymo Research, Orange, CA, USA), and 200 ng of the converted DNA was used for amplification. Amplified DNA was hybridized to the Infinium HumanMethylation27 BeadChip (Illumina), which analyzes the methylation status of 27 578 CpG sites selected from .14 495 well-annotated genes. The arrays were imaged using the BeadArray Reader, and image processing and extraction of intensity data were performed according to the Illumina's instructions. Each methylation signal was used to compute the b-value, which is a quantitative measure of DNA methylation ranging from 0 (for completely unmethylated cytosines) to 1 (for completely methylated cytosines) (15) .
Clustering ESC-, DE-and hepatocyte-specific expressed genes
We wished to identify three clusters of genes in which all gene members show gene expression changes similar to well-known markers of three states during in vitro hepatogenesis. Gene expression microarray data were imported into TIGR MultiExperiment Viewer (42) , and K-means clustering was performed. Filtering and compilations of data were carried out using Microsoft Excel.
Quantitative reverse transcription -PCR (qRT -PCR)
qRT -PCR was performed as described (43) . PCR primer sequences are listed in Supplementary Material, Table S7 . Total RNA was prepared using the RNeasy kit (Qiagen, Hilden, Germany); DNase-treated RNA (5 mg) was reversetranscribed with Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time PCR was performed in a C1000 Thermal Cycler (Bio-Rad, Hercules, CA, USA). The gene encoding b-actin was amplified as a control. Relative quantification of target mRNA was analyzed by comparative threshold cycle (C T ) methods (44) .
Pyrosequencing analysis
Pyrosequencing was performed as described previously (43) . The primers were designed by PSQ Assay Design (Biotage AB, Kungsgatan, Sweden; Supplementary Material, Table S7 ). Bisulfite-modified DNA (EZ DNA methylation kit; Zymo Research) was amplified in a 25 ml reaction with the primer set and f-Taq polymerase (Solgent, Daejeon, Korea). Pyrosequencing reactions were performed on the PSQ HS 96A System (Biotage AB).
MBD-seq
Genomic DNA was fragmented to 100 -500 bp by 44 psi of gas for 1 min through a nebulizer (Illumina) and then subjected to methylated DNA enrichment using the MethylMiner methylated DNA enrichment kit (Invitrogen). Briefly, methylated DNA was precipitated from 1 mg of fragmented genomic DNA via binding to the methyl-CpG-binding domain of human MBD2 protein, which was coupled to magnetic Dynabeads. The methylated fragments were then eluted with HighSalt Elution Buffer (Invitrogen) and purified by the Qiagen miniElute PCR purification kit. The methylated DNA fragments were ligated to a pair of adaptors for sequencing on the Illumina Genome Analyzer. The ligation products were size fractioned to obtain 200 -300 bp fragments on a 2% agarose gel and subjected to 18 cycles of PCR amplification. Cluster generation and 72 cycles of single-read sequencing were done. The sequences were mapped to the human genome (UCSC hg18) using the Illumina Genome Analyzer data analysis pipeline. The entire genome was divided into 200 bp segments, and the number of reads was counted in each segment. The number of reads was normalized against the total number of reads.
Data deposition
Microarray data have been deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE25046 (for gene expression data) and GSE25047 (for DNA-methylation data). The raw sequence tags have been deposited in the NCBI Short Read Archive (SRA) under accession number SRA024341.1.
